Login
$TXMD
$1.83 +$0.02 (1.08%) After hours

$TXMD SEC Filings

Filed On Filing
13 Nov 2026 QUARTERLY REPORT
13 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
11 Aug 2026 QUARTERLY REPORT
11 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—August 11, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months e...

05 Aug 2026 SCHEDULE 13G/A
12 May 2026 QUARTERLY REPORT
12 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—May 12, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ende...

06 Apr 2026 SCHEDULE 13G
01 Apr 2026 ANNUAL REPORT
01 Apr 2026 NOTIFICATION OF LATE FILING
30 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—March 30, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended...

30 Mar 2026 ANNUAL REPORT
21 Jan 2026 8-K: Changes in Registrant's Certifying Accountant

We are the former independent registered public accounting firm for TherapeuticsMD, Inc. (the “Company”).

29 Dec 2025 Form 4: Thompson Tommy G, Director

Bought 8,400 shares ($14K)

16 Dec 2025 8-K: Submission of Matters to a Vote of Security Holders

On December 15, 2025, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), held its 2025 Annual Meeting (the “Annual Meeting”). At the close of business on October 20, 2025, the record date for the determination of stockholders en...

13 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—November 12, 2025 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months...

12 Nov 2025 QUARTERLY REPORT
05 Nov 2025 Form 4: Thompson Tommy G, Director

Granted 8,500 Restricted Stock Units

05 Nov 2025 Form 4: Naughton Gail K, Director

Granted 8,500 Restricted Stock Units

05 Nov 2025 Form 4: Collins Cooper C., Director

Granted 8,500 Restricted Stock Units

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support